Wegovy 0.5 mg FlexTouch Pen (Semaglutide)

Price range: 460.00$ through 1,220.00$

Product Overview Wegovy 0.5 mg FlexTouch Pen is a prescription injectable indicated for chronic weight management in adults who are overweight or obese. The device, manufactured by Novo Nordisk India, comes as a single pre‑filled pen containing 0.5 m

Active Ingredients	Semaglutide
Delivery Time	6 To 15 days
Indication	weight loss and maintenance for overweight or obese adults
Manufacturer	Novo Nordisk India
Packaging	1 Pen & 4 Disposable Needles
Strength	0.5mg

Estimated Delivery: Sun, Jun 28 – Tue, Jun 30

... people are viewing this right now

Guaranteed Safe Checkout

Pack Size	Price	Price/Unit	Quantity
1 Pen	460.00$	460.00$ / Piece	Wegovy 0.5 mg FlexTouch Pen (Semaglutide) quantity
2 Pen/s	840.00$	420.00$ / Piece	Wegovy 0.5 mg FlexTouch Pen (Semaglutide) quantity
3 Pen/s	1,220.00$	406.67$ / Piece	Wegovy 0.5 mg FlexTouch Pen (Semaglutide) quantity

🔒 We Accept — Secure International Payment

Bank Transfer

Wire / SWIFT

Zelle

US bank transfer

Crypto

BTC / ETH / USDT

Venmo

US payment app

After placing your order, you will receive full payment details by email. Your order is dispatched within 24 hours of payment confirmation. You can also order directly via WhatsApp for the fastest service.

🚚 Worldwide Shipping — Fully Tracked & Insured

United States

Standard tracked delivery

7–14 Business Days

United Kingdom

Standard tracked delivery

5–10 Business Days

Australia

Standard tracked delivery

10–18 Business Days

Rest of World

50+ countries available

10–20 Business Days

All orders are shipped in plain, discreet packaging with no pharmacy or medicine reference outside. Tracking number is sent by email after dispatch. Shipped from Mumbai, India.

Description

Product Overview

Wegovy 0.5 mg FlexTouch Pen is a prescription injectable indicated for chronic weight management in adults who are overweight or obese. The device, manufactured by Novo Nordisk India, comes as a single pre‑filled pen containing 0.5 mg of semaglutide and four disposable needles for sub‑cutaneous administration. It is supplied in a packaging unit that includes one pen and the accompanying needles, allowing patients to begin therapy without additional accessories. Storage instructions require refrigeration (2 °C–8 °C) until first use, after which the pen may be kept at room temperature not exceeding 30 °C for up to six weeks. This design supports convenient, long‑term use when combined with a reduced‑calorie diet and increased physical activity, offering a structured option for individuals seeking medically supervised weight loss.

What is Wegovy 0.5 mg FlexTouch Pen (Semaglutide)

Wegovy contains semaglutide, a synthetic analogue of the incretin hormone glucagon‑like peptide‑1 (GLP‑1). The 0.5 mg strength represents the initial dose used to introduce therapy before gradual titration to higher strengths. The FlexTouch system is a needle‑free injection platform that reduces injection pain and improves patient adherence. Semaglutide exerts its pharmacodynamic effect by binding to GLP‑1 receptors in the pancreas, brain, and gastrointestinal tract, where it enhances glucose‑dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and modulates appetite centers in the hypothalamus. These combined actions lead to decreased caloric intake and progressive weight loss when used as part of a comprehensive lifestyle program.

Uses and Benefits

Wegovy is approved for chronic weight management in adults with a body‑mass index (BMI) of 30 kg/m² or greater, or a BMI of 27 kg/m² in the presence of at least one weight‑related comorbidity such as hypertension, type 2 diabetes, or dyslipidemia. Clinical trials have demonstrated that, when combined with dietary modification and increased physical activity, the medication can produce an average reduction in body weight of approximately 15 % after one year of treatment. Additional benefits include improvements in cardiometabolic parameters such as fasting glucose, triglycerides, and blood pressure, which may translate into a lower risk of cardiovascular events. The once‑weekly dosing schedule supports high adherence rates, and the pen’s needle‑free design contributes to patient comfort, facilitating long‑term commitment to therapy. Evidence for the efficacy of semaglutide is documented by the FDA and corroborated by research published through the NIH.

How It Works

The active ingredient semaglutide functions as a selective agonist at the GLP‑1 receptor, a class of proteins that mediate incretin effects. Upon subcutaneous injection, semaglutide circulates systemically and interacts with GLP‑1 receptors located in the pancreatic β‑cells, stimulating glucose‑dependent insulin release while simultaneously suppressing glucagon secretion, thereby improving overall glycemic control. In the central nervous system, activation of GLP‑1 receptors in the arcuate nucleus influences neuropeptide Y and proopiomelanocortin pathways, leading to reduced hunger signals and increased satiety. Peripherally, the drug slows gastric emptying, prolonging the feeling of fullness after meals. These physiological responses collectively create a negative energy balance, resulting in progressive weight loss when patients adhere to recommended lifestyle interventions.

Dosage Guidelines

Therapeutic initiation begins with a 0.25 mg subcutaneous injection once weekly for four weeks, after which the dose is increased to 0.5 mg per week, which is the strength supplied in each pen. Subsequent escalation to 1 mg, 1.7 mg, and 2.4 mg is performed at four‑week intervals, contingent upon tolerability and clinical response. Each pen delivers a single 0.5 mg dose and includes four disposable needles for injection at the abdomen, thigh, or upper arm. Patients should rotate injection sites to minimize local skin irritation. The device must be stored refrigerated until first use; after first use it may be kept at ambient temperature not exceeding 30 °C for up to six weeks. Detailed administration instructions are provided in the product leaflet and should be reviewed with a healthcare professional before self‑administration.

Side Effects

Most adverse events associated with Wegovy are mild to moderate and typically occur during the early phases of treatment. The most frequently reported symptoms include nausea, vomiting, diarrhea, constipation, and abdominal discomfort, which often diminish after a few weeks as the body adapts. Less common but clinically important side effects comprise hypoglycemia when used in combination with insulin or sulfonylureas, acute pancreatitis, and gallbladder disease such as cholelithiasis. Rarely, cases of thyroid C‑cell tumors have been observed in animal studies; the relevance to humans is uncertain, but the drug is contraindicated in individuals with a personal or family history of medullary thyroid carcinoma. Patients experiencing severe abdominal pain, persistent vomiting, or signs of an allergic reaction such as rash, swelling, or respiratory difficulty should seek medical attention promptly.

Warnings and Precautions

Wegovy is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN 2). The medication should not be used during pregnancy or while breastfeeding, as the safety of semaglutide in these populations has not been established. Caution is advised in individuals with a prior history of pancreatitis, severe gastrointestinal disease, or renal impairment, who should be monitored closely for worsening symptoms. Regular laboratory assessments of thyroid function and pancreatic health are recommended for patients on long‑term therapy. Additionally, healthcare providers should screen for psychiatric concerns, as GLP‑1 receptor agonists have been associated with rare cases of suicidal ideation. Interaction with other weight‑loss pharmacotherapies is not recommended without medical supervision, and patients should be advised to maintain regular follow‑up visits to evaluate efficacy and safety.

Frequently Asked Questions

1. Who should consider starting Wegovy treatment? Adults with a BMI of 30 kg/m² or higher, or a BMI of 27 kg/m² accompanied by at least one weight‑related condition such as hypertension, type 2 diabetes, or dyslipidemia, who are committed to participating in a structured diet and exercise program, are appropriate candidates.

2. How soon can weight loss be expected? Most clinical studies report measurable reductions in body weight after approximately 12 weeks of therapy, with more pronounced losses emerging by the end of the 68‑week treatment period. Individual results vary based on baseline weight, adherence, and metabolic factors.

3. Can Wegovy be combined with other weight‑loss medications? Concomitant use of other GLP‑1 receptor agonists or prescription weight‑loss agents is not recommended without explicit medical guidance, as combining therapies may increase the risk of adverse effects and has not been studied extensively.

4. What should I do if I miss a scheduled injection? If a dose is missed, the next injection should be administered as soon as possible provided at least three days have passed since the previous dose. The regular once‑weekly schedule should then be resumed; doses should not be doubled.

5. Is long‑term use of Wegovy considered safe? Extended treatment periods of up to 68 weeks have demonstrated a manageable safety profile when patients undergo regular monitoring for thyroid function, pancreatic health, and overall metabolic status. Ongoing medical supervision is essential to address any emerging concerns.